Solara Trial Strategy Platform Da Volterra Case Study | Cytel

Biotech innovator Da Volterra leverages Solara™ to de-risk their clinical trial and optimize commercial strategy.

Challenged by a strict enrollment limit of 1,100 patients, Da Volterra had a sample size re-estimation (SSR) design that only produced marginal gains in power over the fixed sample size.

Facing the risk that a sub-optimal design would prevent a good drug from reaching patients, Da Volterra’s Chief Medical Officer sought a way to consider options that conventional wisdom would ignore.

Working with Cytel’s statistical consultants and their powerful new trial strategy platform Solara TM , in less than 2 hours Da Volterra was able to examine:

● 151.2 million patient lives simulated
● 1,512 combinations of design options and scenario variants

Find out how Da Volterra was able to use Solara’s revolutionary capabilities to rapidly prioritize design options and confidently select a low-risk trial design within hours.

Download the case study to discover how Solara enabled Da Volterra to rapidly identify a trial design with reduced the risk of faulty conclusions.

Enter your information to read the case study

 

"We found an optimal design in hours that might have taken months to find using standard methods.”

- Chief Medical Officer, Da Volterra

Screenshot 2021-06-02 at 16.26.17